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Plan
AngioMax is a single dose heparin alternative 
introduced in 2002 that is used in cardiac patients 
undergoing percutaneous intervention (PCI). 
Bivalirudin and heparin are both acceptable options 
according to current ACA/AHA guidelines. 
Bivalirudin costs $377 per dose; Heparin is less than 
$15 per dose. Noting practice variation, the Cath 
Lab set out to eliminate unnecessary pharmacy cost 
for PCI patients by:
• Using current literature to inform clinical care 
• Standardizing practice 
• Using data to track and guide implementation  
Do
• Explore variation in utilization of Bivalirudin and 
Heparin in PCI cases 
• Share lit review findings:  Given the significant 
cost difference between bivalirudin and heparin, 
heparin should be the preferred agent for STEMI 
PCI except in patients at extreme risk of bleeding.
• Engage Cath Lab leadership and Interventional 
Cardiology providers to evaluate current practice
• Track monthly utilization and use data to inform 
implementation plans
Team Members
Scott Scepaniak, RN, CEN -- Cardiac Cath Lab 
Phil Martin, MBA BSN RN -- Section Director 
Kristi Patterson, BSN RN, CPHQ – PIVA
Dr. Dan Tiede – Cardiology
Study Act
• Generate discussion by sharing data 
demonstrating the variation in AngioMax use
• Use adaptive leadership skills to spread practice 
change throughout Interventional Cardiology
• Share monthly AngioMax utilization with the Cath 
Lab Team and Interventional Cardiology
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Summer 2017
• Cath lab begins exploring 
the variation in blood 
thinners used during PCI & 
current best practices 
Early Fall 2017
• Cath Lab staff engages 
Interventional Cardiology, 
provides group and 1:1 
education 
October 2017
• Monthly reporting data  used 
to evaluate implementation 
and identify potential areas 
of opportunity
Cost Savings due to decreased use of AngioMax for IP and OP PCI in the first 8 
months of implementation:  >$100,000
Begin Intentional Conversations 
Regarding Practice Variation 
